ALNY icon

Alnylam Pharmaceuticals
ALNY

Overview Fund Activity

235 hedge funds and large institutions have $10.3B invested in Alnylam Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 68 increasing their positions, 85 reducing their positions, and 33 closing their positions.

Holders
235
Holders Change
+9
Holders Change %
+3.98%
% of All Funds
5.87%
Holding in Top 10
12
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+50%
% of All Funds
0.3%
New
45
Increased
68
Reduced
85
Closed
33
Calls
$392M
Puts
$323M
Net Calls
+$69.2M
Net Calls Change
+$60.5M

Top Buyers

1
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$1.01B
2
BlackRock
2
BlackRock
New York
$718M
3
O
3
OrbiMed
New York
$127M
4
Goldman Sachs
4
Goldman Sachs
New York
$211M
5
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$115M

Top Sellers

1
SPC
1
Slate Path Capital
New York
$65.9M
2
Wellington Management Group
2
Wellington Management Group
Massachusetts
$1.33B
3
RI
3
RTW Investments
New York
$73.2M
4
TCIM
4
TIAA CREF Investment Management
New York
$12.6M
5
BM
5
Bridger Management
New York
$45.1M
Name Market Value Shares Shares
Change 		Shares
Change %
Fidelity Investments
1
Fidelity Investments
Massachusetts
$1.62B 13,760,005 +36,852 +0.3%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$1.33B 11,301,317 -567,731 -5%
Dodge & Cox
3
Dodge & Cox
California
$1.07B 9,141,495 -44,325 -0.5%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$1.01B 8,564,883 +1,896,280 +28%
Vanguard Group
5
Vanguard Group
Pennsylvania
$763M 6,492,898 +73,390 +1%
BlackRock
6
BlackRock
New York
$718M 6,111,697 +923,506 +18%
Baillie Gifford & Co
7
Baillie Gifford & Co
United Kingdom
$400M 3,405,392 -25,924 -0.8%
State Street
8
State Street
Massachusetts
$240M 2,043,321 +106,170 +5%
Goldman Sachs
9
Goldman Sachs
New York
$211M 1,793,751 +282,039 +19%
PA
10
Perceptive Advisors
New York
$210M 1,788,802 -43,959 -2%
BRC
11
Blue Ridge Capital
New York
$180M 1,531,899 +155,199 +11%
UBS AM
12
UBS AM
Illinois
$160M 1,364,397 -84,118 -6%
GGHC
13
Gilder Gagnon Howe & Co
New York
$132M 1,120,555 -64,825 -5%
BB
14
BB Biotech
Switzerland
$131M 1,111,338 -110,000 -9%
O
15
OrbiMed
New York
$127M 1,084,800 +445,600 +70%
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$115M 982,454 +248,804 +34%
Morgan Stanley
17
Morgan Stanley
New York
$115M 979,823 -37,708 -4%
First Trust Advisors
18
First Trust Advisors
Illinois
$92.2M 784,619 +158,288 +25%
1WCM
19
12 West Capital Management
New York
$82.2M 700,000 – –
Janus Henderson Group
20
Janus Henderson Group
United Kingdom
$80.2M 683,020 +15,687 +2%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$77.5M 659,527 -2,878 -0.4%
RI
22
RTW Investments
New York
$73.2M 623,338 -417,269 -40%
SPC
23
Slate Path Capital
New York
$65.9M 561,000 -574,000 -51%
Norges Bank
24
Norges Bank
Norway
$65.2M 555,019 -189,396 -25%
ACH
25
ArrowMark Colorado Holdings
Colorado
$59.2M 503,889 -34,400 -6%
1
2 3 4 5